Literature DB >> 14127375

SKIN PIGMENTATION AND CORNEAL AND LENS OPACITIES WITH PROLONGED CHLORPROMAZINE THERAPY.

A C GREINER, K BERRY.   

Abstract

Previously undescribed ocular and dermatologic complications of prolonged chlorpromazine therapy have been noted in 70 patients of a series of many thousands receiving similar therapy. All affected patients were women who had been receiving high doses of chlorpromazine, averaging 500 to 1500 mg. daily, for at least three to five years before the complications became apparent. Skin manifestations consisted of a peculiar purplish pigmentation of the skin of exposed areas of the face, neck and hands, characterized histologically by deposition of material with the staining properties of melanin in the superficial layers of the dermis, particularly in a perivascular distribution. Ocular complications consisted of granular opacity of the cornea and often of the lens as well, the latter producing a central stellate type of cataract.

Entities:  

Keywords:  CHLORPROMAZINE TOXICOLOGY; CORNEAL OPACITY; OPHTHALMOLOGY; PIGMENTATION DISORDERS; TOXICOLOGIC REPORT

Mesh:

Substances:

Year:  1964        PMID: 14127375      PMCID: PMC1922413     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN: 0008-4409            Impact factor:   8.262


  6 in total

1.  Structural effects of tranquilizers.

Authors:  L ROIZIN; C TRUE; M KNIGHT
Journal:  Res Publ Assoc Res Nerv Ment Dis       Date:  1959

2.  Symposium on metabolic diseases of the eye. Galactosemia.

Authors:  D P GREAVES
Journal:  Proc R Soc Med       Date:  1963-01

3.  Six months observation of psychotic identical twins.

Authors:  D W SWANSON
Journal:  Am J Psychiatry       Date:  1961-08       Impact factor: 18.112

4.  An appraisal of chlorpromazine; general principles for administration of chlorpromazine, based on experience with 1,090 patients.

Authors:  N W WINKELMAN
Journal:  Am J Psychiatry       Date:  1957-05       Impact factor: 18.112

5.  Allergenicity of tranquilizing drugs.

Authors:  C BERNSTEIN; S D KLOTZ
Journal:  J Am Med Assoc       Date:  1957-03-16

6.  Toxic amblyopia from perphenazine (fentazin).

Authors:  W JOHNSON
Journal:  J Ment Sci       Date:  1960-01
  6 in total
  20 in total

1.  Chlorpromazine-induced cutaneous pigmentation--effect of replacement with clozapine.

Authors:  S Lal; S Lal
Journal:  J Psychiatry Neurosci       Date:  2000-05       Impact factor: 6.186

2.  SKIN PIGMENTATION, CORNEAL AND LENS OPACITIES WITH PROLONGED CHLORPROMAZINE TREATMENT.

Authors:  L W MASSEY
Journal:  Can Med Assoc J       Date:  1965-01-23       Impact factor: 8.262

3.  Chlorpromazine-induced skin pigmentation with short-term use in a patient with bipolar disorder: a case report.

Authors:  Santosh Loganathan
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2007

Review 4.  Ocular adverse effects of common psychotropic agents: a review.

Authors:  Sami Richa; Jean-Claude Yazbek
Journal:  CNS Drugs       Date:  2010-06       Impact factor: 5.749

5.  Effects of prolonged phenothiazine intake on psychotic and other hospitalized children.

Authors:  J B McAndrew; Q Case; D A Treffert
Journal:  J Autism Child Schizophr       Date:  1972 Jan-Mar

6.  Toxic effects of phenothiazines on the eye.

Authors:  D J Boet
Journal:  Doc Ophthalmol       Date:  1970-07-24       Impact factor: 2.379

7.  A peculiar photosensitivity reaction with chlorpromazine.

Authors:  J A Barsa; J C Saunders
Journal:  Psychopharmacologia       Date:  1965-02-15

8.  Replacement of chlorpromazine with other neuroleptics: effect on abnormal skin pigmentation and ocular changes.

Authors:  S Lal; D Bloom; B Silver; B Desjardins; B Krishnan; J Thavundayil; T Thompson
Journal:  J Psychiatry Neurosci       Date:  1993-07       Impact factor: 6.186

9.  Methotrimeprazine-induced corneal deposits and cataract revealed by urine drug profiling test.

Authors:  Seong Taeck Kim; Jae Woong Koh; Joon Mo Kim; Won Young Kim; Gwang Ju Choi
Journal:  J Korean Med Sci       Date:  2010-10-26       Impact factor: 2.153

10.  Progression of amiodarone induced cataracts.

Authors:  A J Flach; B J Dolan
Journal:  Doc Ophthalmol       Date:  1993       Impact factor: 2.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.